ReachMD CME
By ReachMD
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by ReachMD
Category: Science
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 17
Reviews: 0
Episodes: 396
Description
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.
| Episode | Date |
|---|---|
|
Unblocking Clinical Inertia: The CMI Era in oHCM Care
|
Jun 16, 2026 |
|
FXIa Remix! Keeping the Flow Without Missing a Beat
|
May 08, 2026 |
|
Putting It All Together: Challenges Addressed
|
May 01, 2026 |
|
Genetic Susceptibility in IBD: From Risk Genes to Clinical Impact
|
May 01, 2026 |
|
Understanding the Microbiome’s Role in IBD Management
|
May 01, 2026 |
|
Beyond Biology: Environmental and Lifestyle Influences in IBD
|
May 01, 2026 |
|
Targeting Inflammation in IBD: Localized vs Systemic Strategies
|
May 01, 2026 |
|
Pathophysiology of IBD: The War Within
|
May 01, 2026 |
|
IBD Beyond Symptoms: What Community GIs Need to Know
|
May 01, 2026 |
|
Emerging Focus in NAION: Sharpening Diagnostic Precision for Tomorrow’s Treatments
|
Apr 30, 2026 |
|
Calming Overactive Immune Response and Reducing Inflammation with TYK2 Inhibition in Psoriasis
|
Apr 30, 2026 |
|
Navigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
|
Apr 30, 2026 |
|
NPS Agitation: Evidence and Emerging Mechanisms of Management
|
Apr 28, 2026 |
|
NPS Psychosis: Circuits, Treatment, and New Hope
|
Apr 28, 2026 |
|
Unseen Impact of NPS in AD: Domains and Burden
|
Apr 28, 2026 |
|
Tau Therapies and Clinical Translation: Mechanistic Approaches
|
Apr 28, 2026 |
|
Amyloid-β Therapies in Practice: Not All Are Created Equal
|
Apr 28, 2026 |
|
Key Takeaways and Practice Integration
|
Apr 28, 2026 |
|
Return and Revisit: A 38-Year-Old Patient Returns for Follow-up After Lotilaner Treatment
|
Apr 28, 2026 |
|
Closing the Loop: Structured Follow-Up and Patient Communication
|
Apr 28, 2026 |
|
The Neverending Journey: A 66-Year-Old Patient Who Has Undergone Several Rounds of Tea Tree Oil–Based Treatment
|
Apr 28, 2026 |
|
Moving Beyond Lid Hygiene: Evidence-Based Treatment Strategies
|
Apr 28, 2026 |
|
The Missed Diagnosis: A 45-Year-Old Software Engineer Who Complains of Dry Eyes
|
Apr 28, 2026 |
|
At the Intersection of DB, DED, MGD, and Other Forms of Blepharitis
|
Apr 28, 2026 |
|
Catching Demodex in the Act
|
Apr 28, 2026 |
|
Living With Systemic Mastocytosis: Bridging Clinical Decisions and Patient Realities
|
Apr 24, 2026 |
|
Precision Strikes in AML: Navigating the Evolving Landscape of Targeted Therapies
|
Apr 23, 2026 |
|
Hidden in Plain Sight: A Modern Guide to Detecting and Managing Early Neurotrophic Keratitis
|
Apr 20, 2026 |
|
Beyond IOP: Integrating Ocular Surface Resilience Into Glaucoma Management
|
Apr 20, 2026 |
|
Retina Rumble: Debating Modern Treatment Options
|
Apr 15, 2026 |
|
Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
|
Apr 10, 2026 |
|
Leveraging CGM to Its Full Potential in People with T2D
|
Apr 08, 2026 |
|
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
|
Apr 07, 2026 |
|
The Future of HNSCC: Aligning Teams, Transforming Care
|
Mar 31, 2026 |
|
Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
|
Mar 31, 2026 |
|
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
|
Mar 31, 2026 |
|
Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
|
Mar 26, 2026 |
|
Safety in oHCM Therapy: How and When to Transition Treatment?
|
Mar 26, 2026 |
|
From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
|
Mar 26, 2026 |
|
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
|
Mar 26, 2026 |
|
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
|
Mar 26, 2026 |
|
Molecular Precision: How Myosin Inhibitors Redefine Control
|
Mar 26, 2026 |
|
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
|
Mar 26, 2026 |
|
Cracking the Code of Obstruction: Unmet Needs in oHCM
|
Mar 26, 2026 |
|
Beyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
|
Mar 26, 2026 |
|
FcRn: Same Class, Different Paths—Spot Agent Differentiators
|
Mar 24, 2026 |
|
The 2-Point Signal: Apply ≥2-Point Rule
|
Mar 24, 2026 |
|
Shared Goals, Shared Gains: Align With Patient Preferences
|
Mar 24, 2026 |
|
Escalate With Intention: Stepwise, Target-Anchored Moves
|
Mar 24, 2026 |
|
The IgG Clock: Redose Using IgG Kinetics
|
Mar 24, 2026 |
|
When to Begin FcRn: Initiation Criteria, Key Evidence
|
Mar 24, 2026 |
|
Turning Flares Into Function: Flag Uncontrolled Disease
|
Mar 24, 2026 |
|
Minimal By Design: Define MSE Endpoints
|
Mar 24, 2026 |
|
Target Locked in gMG: Why T2T Matters
|
Mar 24, 2026 |
|
Patient Voices and Provider Partnerships to Advance Cardio-Kidney-Metabolic Outcomes
|
Mar 19, 2026 |
|
DKA in Focus: What the New Consensus Means for Practice
|
Mar 19, 2026 |
|
Applying Advances in Practice: Case-Based Look at Selecting Therapy for Cushing Syndrome
|
Mar 13, 2026 |
|
Shifting the Script: Personalizing Overactive Bladder Treatment in Complex Patients
|
Mar 13, 2026 |
|
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
|
Mar 10, 2026 |
|
Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
|
Mar 10, 2026 |
|
Emerging Therapies in IgAN: Who Could Benefit the Most?
|
Mar 10, 2026 |
|
Emerging Evidence: IgAN Disease-Modifying Agents
|
Mar 10, 2026 |
|
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
|
Mar 10, 2026 |
|
IgAN SOC: Strengths and Limits
|
Mar 10, 2026 |
|
Mechanism-Based Targeting: Why APRIL Matters in IgAN
|
Mar 10, 2026 |
|
APRIL Uncovered: An Upstream Driver in IgAN
|
Mar 10, 2026 |
|
The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
|
Mar 10, 2026 |
|
Breaking Ground: 2025 Milestones in Cushing Syndrome and Looking Forward to 2026
|
Mar 06, 2026 |
|
So You Think You Want a TKI?
|
Mar 04, 2026 |
|
Who Needs a TKI? Identifying the Right Candidates
|
Mar 04, 2026 |
|
To Implant or to Inject?
|
Mar 04, 2026 |
|
TKI: The New TKO for Retinal Diseases
|
Mar 04, 2026 |
|
The Struggle Is Real
|
Mar 04, 2026 |
|
Inside the IgAN Clinic: Shared Decision-Making Into Practice
|
Feb 24, 2026 |
|
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
|
Feb 16, 2026 |
|
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
|
Feb 16, 2026 |
|
Safety, Clinical Integration, and the Emerging Fifth Pillar in HF Practice
|
Feb 13, 2026 |
|
Evidence at a Glance: The Totality of Evidence Impacting Clinical Decision-Making in Patients with HFrEF Without a Recent Worsening Event
|
Feb 13, 2026 |
|
Do Not Delay: Timing, Triggers, and Identifying the Right Patient for Additional Therapies in HFrEF
|
Feb 13, 2026 |
|
GDMT Is Working Fine, Why Add More Therapies? The Clinical Rationale for Layering Therapies in Patients with HFrEF
|
Feb 13, 2026 |
|
When GDMT Isn’t Enough: Understanding Residual Risk in Patients with HFrEF
|
Feb 13, 2026 |
|
GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
|
Feb 10, 2026 |
|
Targeting B7-H3 in ES-SCLC: Advancing Targeted Therapy Through Evidence-Based Innovation and Multidisciplinary Care
|
Feb 10, 2026 |
|
Test Your Skills and Learn From Experts on Best Practice in Diagnosis and Management of Systemic Mastocytosis
|
Feb 09, 2026 |
|
Early Clues, Lasting Impact: Detecting and Treating Alzheimer’s Disease in Its Earliest Stages
|
Feb 06, 2026 |
|
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
|
Jan 30, 2026 |
|
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
|
Jan 30, 2026 |
|
Progress in Breast Cancer Care: Translating SABCS Data Into Practice
|
Jan 30, 2026 |
|
Missing the Window in Ambulatory Patients With HFrEF on GDMT: Strategies for CV Risk Reduction
|
Jan 30, 2026 |
|
Personalizing First-Line Therapy for CLL
|
Jan 30, 2026 |
|
Double-Class Refractory CLL in Community Practice: Current and Future Management
|
Jan 30, 2026 |
|
Navigating Treatment Sequencing After Frontline Treatment Failure in CLL
|
Jan 30, 2026 |
|
It Takes a Village, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
|
Jan 30, 2026 |
|
A Case of Missed Diagnosis, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
|
Jan 30, 2026 |
|
Patient at High Risk of Loss to Follow-Up, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
|
Jan 30, 2026 |
|
Overcoming Cultural and Communication Disconnects, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
|
Jan 30, 2026 |
|
RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
|
Jan 29, 2026 |
|
Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
|
Jan 29, 2026 |
|
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors
|
Jan 29, 2026 |
|
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
|
Jan 29, 2026 |
|
Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
|
Jan 29, 2026 |
|
Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
|
Jan 29, 2026 |
|
Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
|
Jan 29, 2026 |
|
RAS Across Tumors: Who to Test When
|
Jan 29, 2026 |
|
From Pixels to Practice: Advancing HCM Care With Multimodality Imaging
|
Jan 28, 2026 |
|
Frontline Insights: Emerging Therapeutic Strategies in HNSCC
|
Jan 27, 2026 |
|
Breaking the Line: Moving Bispecific Antibodies Upstream in Treating Multiple Myeloma
|
Jan 23, 2026 |
|
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
|
Jan 16, 2026 |
|
Interdisciplinary Strategies for BRCA-Mutated EBC: Testing, Targeting, and Team-Based Care
|
Jan 15, 2026 |
|
Oh, the Hats You'll Wear! The Many Modalities of Pediatric Obesity Management
|
Jan 06, 2026 |
|
Addressing Unmet Needs in Metastatic Uveal Melanoma
|
Jan 05, 2026 |
|
Spotlight on Systemic Sclerosis: Pathophysiology, Presentation, & Emerging Evidence
|
Jan 05, 2026 |
|
Patients First: Navigating Asparaginase-Based Treatment in Young Adults With ALL
|
Jan 02, 2026 |
|
Case Review: Targets Are Met—Can You Stick the Landing?
|
Dec 31, 2025 |
|
Switching Strategies: Switch or Stay—What’s Your Call?
|
Dec 31, 2025 |
|
Remission: Can You Prove It?
|
Dec 31, 2025 |
|
Treat-to-Target: Are We There Yet?
|
Dec 31, 2025 |
|
Case Review: Can You Crack This IBD Case?
|
Dec 31, 2025 |
|
Tailoring Treatment: Can You Select the Best Therapy?
|
Dec 31, 2025 |
|
IBD Immunopathogenesis: Do You Know What You're Blocking?
|
Dec 31, 2025 |
|
Severity Assessment: Can You Pin the Stage on the Patient?
|
Dec 31, 2025 |
|
Diagnosing IBD: Is It IBD or Something Else? Can You Tell?
|
Dec 31, 2025 |
|
Practical Perspectives in Myasthenia Gravis #3: Therapeutic Selection and Monitoring Efficacy—Matching Mechanisms to Patients
|
Dec 31, 2025 |
|
Practical Perspectives in Myasthenia Gravis #2: Patient Stratification and Antibody Profiling—Personalizing the Disease Lens
|
Dec 31, 2025 |
|
Practical Perspectives in Myasthenia Gravis # 1: Diagnostic Logistics—Navigating Complexity Across Ages
|
Dec 31, 2025 |
|
Earlier Action, Lasting Impact: Closing the LDL-C Gap in Patients Without a Prior MACE
|
Dec 30, 2025 |
|
A New Paradigm in IgAN Management—Advancing Clinical Practice in the Era of Therapeutic Expansion
|
Dec 29, 2025 |
|
Hitting the Target in Atopic Dermatitis: Interdisciplinary Team Training for Leveraging IL-13 Inhibitors to Address the Burden of Disease
|
Dec 26, 2025 |
|
Primary Care for the Brain: Prevention and Early Detection of Cognitive Decline
|
Dec 26, 2025 |
|
Decoding EGPA: A Clinical Deep Dive Into Diagnosis and Treatment
|
Dec 23, 2025 |
|
When Topicals Fail: The New IPC Consensus Every Clinician Should Know
|
Dec 22, 2025 |
|
New Pathways in the Treatment of DMD
|
Dec 19, 2025 |
|
Nephrology at the Helm—Advancing Timely CKD Care Through Cross-Specialty Collaboration
|
Dec 18, 2025 |
|
Optimizing Multidisciplinary Approaches in the Guideline-Driven Management of Cervical and Endometrial Cancers
|
Dec 16, 2025 |
|
Are You On Top of Pediatric Atopic Dermatitis? Expert Guidance for Leveraging the Latest Advances in Systemic Therapy
|
Dec 15, 2025 |
|
All Sides of the Joint: Integrated TGCT Care Across Specialties
|
Dec 15, 2025 |
|
Patient Perspective: Navigating TGCT Treatment—Surgery vs Systemic Therapy
|
Dec 15, 2025 |
|
The Safety Equation: Managing Adverse Events Associated With CSF1R Inhibitors in TGCT
|
Dec 15, 2025 |
|
Applying the Evidence: TGCT Treatment Insights for Sports Medicine Physicians
|
Dec 15, 2025 |
|
Emerging Evidence in Focus: Interpreting Data on Next-Generation CSF1R TKIs
|
Dec 15, 2025 |
|
Surgical Crossroads: Practical Considerations for Optimizing Treatment in TGCT
|
Dec 15, 2025 |
|
Clinical Evidence in Focus: Interpreting Data on Systemic Therapy Targeting CSF1R
|
Dec 15, 2025 |
|
Unlocking the CSF1R Code: Targeted Pathways and Tailored Choices
|
Dec 15, 2025 |
|
Beyond the Scalpel: When TGCT Surgery Isn’t the Solution
|
Dec 15, 2025 |
|
The Tumor That’s Not So Tiny: Understanding the Impact of TGCT
|
Dec 15, 2025 |
|
Implementing the Latest Diagnostic and Treatment Approaches for Generalized Myasthenia Gravis
|
Dec 15, 2025 |
|
Advances in the Treatment of Overt Hepatic Encephalopathy: What's in the Pipeline?
|
Dec 11, 2025 |
|
Current Treatment of Hepatic Encephalopathy: Is It Meeting Our Patients' Needs?
|
Dec 11, 2025 |
|
Optimizing Care of the Hospitalized Patient With Overt Hepatic Encephalopathy
|
Dec 11, 2025 |
|
Treatment of Hepatic Encephalopathy: Primary vs Secondary Prophylaxis
|
Dec 11, 2025 |
|
Treatment of Hepatic Encephalopathy: When, What, How, and Why?
|
Dec 11, 2025 |
|
The Slippery Slope of Overt Hepatic Encephalopathy
|
Dec 11, 2025 |
|
Minimal Hepatic Encephalopathy: A Covert Operation?
|
Dec 11, 2025 |
|
Minimal Hepatic Encephalopathy: Hiding in Plain Sight?
|
Dec 11, 2025 |
|
Hepatic Encephalopathy: More Common Than You Think
|
Dec 11, 2025 |
|
Advances in Treatment of Hypoparathyroidism: Importance of Genetic Testing for Autosomal Dominant Hypocalcemia Type 1
|
Dec 10, 2025 |
|
Taking Action Against RSV: No Child Unprotected
|
Dec 04, 2025 |
|
Early Action in Obesity: Transforming Practice, Improving Outcomes
|
Dec 03, 2025 |
|
Future mCRC Directions: Enhancing Anti-EGFR Therapy With Novel Combination Strategies
|
Dec 02, 2025 |
|
Future-Proofing in HAE: Advances in Long-term Prophylaxis to Prevent Attacks and Improve Quality of Life
|
Dec 02, 2025 |
|
Rethinking Schizophrenia Treatment Through Muscarinic Modulation
|
Dec 02, 2025 |
|
A Clear Horizon in Plaque Psoriasis: An Update on Investigational Oral Therapies
|
Nov 26, 2025 |
|
IgAN Management Into Practice: Evolving Guidelines & Targeted Therapies
|
Nov 19, 2025 |
|
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
|
Nov 18, 2025 |
|
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
|
Nov 14, 2025 |
|
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
|
Nov 14, 2025 |
|
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
|
Nov 14, 2025 |
|
MOA: CDH6-Targeted Antibody-Drug Conjugates
|
Nov 14, 2025 |
|
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
|
Nov 14, 2025 |
|
The Fifth Pillar? Closing the Gap in HFrEF
|
Nov 14, 2025 |
|
Advancing gMG Clinical Decisions: Diagnosing Early, Treating Smarter, and Caring Holistically – A Case-Based Treatment Approach
|
Nov 13, 2025 |
|
Treating MASH With Compensated Cirrhosis: A Serious Unmet Need
|
Nov 11, 2025 |
|
Advancing Clinical Expertise in CELMoDs: Transforming Multiple Myeloma Treatment
|
Nov 10, 2025 |
|
Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape
|
Nov 07, 2025 |
|
Updates in Major Depressive Disorder with Insomnia
|
Nov 07, 2025 |
|
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum
|
Nov 05, 2025 |
|
Breaking the Cycle: Prioritizing Weight Loss to Improve OSA Management
|
Oct 31, 2025 |
|
Case Applications in Multidisciplinary Care for Endometrial Cancer
|
Oct 31, 2025 |
|
Applications in Multidisciplinary Care for Cervical Cancer
|
Oct 31, 2025 |
|
Managing Immune-Related Adverse Events in Cervical and Endometrial Cancer
|
Oct 31, 2025 |
|
Evidence Base for Treatment Strategies for Endometrial Cancer After Disease Progression and Interdisciplinary Collaboration
|
Oct 31, 2025 |
|
Evidence Base for First-Line Treatment Strategies for Endometrial Cancer and Delivering Guideline-Concordant Care
|
Oct 31, 2025 |
|
Role of Predictive Biomarkers in Endometrial Cancer
|
Oct 31, 2025 |
|
Evidence- and Guideline-Based Treatment for Advanced/Metastatic Cervical Cancer
|
Oct 31, 2025 |
|
Screening for Cervical Cancer
|
Oct 31, 2025 |
|
Interdisciplinary Management of Gynecologic Cancers
|
Oct 31, 2025 |
|
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD
|
Oct 31, 2025 |
|
Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
|
Oct 30, 2025 |
|
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
|
Oct 29, 2025 |
|
The Patient-Clinician Connection in Managing CKD-aP
|
Oct 24, 2025 |
|
Improving Sleep and Mental Health in Patients with CKD-aP
|
Oct 24, 2025 |
|
Kappa-Opioid Settings: Real-World Evidence Insights
|
Oct 24, 2025 |
|
Is CKD-aP Hiding in Your Dialysis Center?
|
Oct 24, 2025 |
|
Elevating CKD-aP Care: New Frontier
|
Oct 24, 2025 |
|
CKD-aP Treatment Tool Kit
|
Oct 24, 2025 |
|
CKD-aP or Something Else? Decoding the Diagnosis
|
Oct 24, 2025 |
|
Quantifying CKD-aP: Tools for Better Care
|
Oct 24, 2025 |
|
CKD-aP: Beyond the Surface
|
Oct 24, 2025 |
|
Advances in the Treatment of Hepatic Encephalopathy
|
Oct 23, 2025 |
|
Hepatic Encephalopathy: Unmet Therapeutic Needs
|
Oct 23, 2025 |
|
Treatment of Overt Hepatic Encephalopathy
|
Oct 23, 2025 |
|
Hepatic Encephalopathy: What's Sarcopenia Got to Do With It?
|
Oct 23, 2025 |
|
Diagnosing Minimal Hepatic Encephalopathy: There's an App for That?
|
Oct 23, 2025 |
|
You Can’t Diagnose MHE Unless You Diagnose Cirrhosis
|
Oct 23, 2025 |
|
Hepatic Encephalopathy: Tipping the Balance
|
Oct 23, 2025 |
|
The Clinical Spectrum of Hepatic Encephalopathy
|
Oct 23, 2025 |
|
Hepatic Encephalopathy: An Ominous Sign
|
Oct 23, 2025 |
|
Not Just a Headache: Migraine Across Women’s Lifespan
|
Oct 23, 2025 |
|
Global Perspectives on Data in Type 2 Diabetes — Congress-to-Clinic Insights
|
Oct 22, 2025 |
|
ENDOVOICE Live: Endometriosis—A Chronic Burden of Reproductive Years
|
Oct 22, 2025 |
|
Primary Biliary Cholangitis: Shining Light on an "Invisible" Female Health Burden
|
Oct 22, 2025 |
|
Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
|
Oct 21, 2025 |
|
Diagnosing and Treating IBS: It Begins With One Simple Question
|
Oct 20, 2025 |
|
Women’s Sleep Health – Addressing Gaps in OSA Diagnosis and Treatment Across Life Stages
|
Oct 15, 2025 |
|
The Future of PI3K Inhibition in HR+/HER2- Breast Cancer
|
Oct 07, 2025 |
|
PI3K Pathway Inhibitors: Safety and Tolerability Profiles
|
Oct 07, 2025 |
|
Case in Point: Applying PI3K Combinations in Early Recurrent HR+/HER2- mBC
|
Oct 07, 2025 |
|
Triple Threat: Key Data on Simultaneous Estrogen, CDK4/6, and PI3K Inhibition in mBC
|
Oct 07, 2025 |
|
Double Take: Pivotal Data Evaluating PI3K Inhibitor/Endocrine Therapy Regimens in mBC
|
Oct 07, 2025 |
|
Comprehensive Biomarker Testing in mBC Informs Clinical Decision Making
|
Oct 07, 2025 |
|
PI3K Pathway Inhibition in HR+/HER2- mBC: Mechanistic Insights
|
Oct 07, 2025 |
|
Understanding Endocrine Resistance in HR+/HER2- mBC
|
Oct 07, 2025 |
|
Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
|
Oct 03, 2025 |
|
Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
|
Oct 01, 2025 |
|
Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer
|
Sep 30, 2025 |
|
Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
|
Sep 30, 2025 |
|
Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers
|
Sep 30, 2025 |
|
Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers
|
Sep 30, 2025 |
|
Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
|
Sep 26, 2025 |
|
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025
|
Sep 26, 2025 |
|
Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
|
Sep 26, 2025 |
|
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC
|
Sep 26, 2025 |
|
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
|
Sep 26, 2025 |
|
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC
|
Sep 26, 2025 |
|
From Resistance to Response: Evolving Strategies in MDD Management
|
Sep 26, 2025 |
|
Future Directions in Managing Hyperkalemia in CKD and HF
|
Sep 24, 2025 |
|
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
|
Sep 24, 2025 |
|
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
|
Sep 24, 2025 |
|
Potassium Binders: Safety Comes First!
|
Sep 24, 2025 |
|
Potassium Binders in Practice: Clinical Trial Evidence
|
Sep 24, 2025 |
|
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF
|
Sep 24, 2025 |
|
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
|
Sep 24, 2025 |
|
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
|
Sep 24, 2025 |
|
The Critical Interplay: CKD, HF, and HyperkaleAmia
|
Sep 24, 2025 |
|
Bronchiectasis Update: Diagnostic Innovations and Therapeutic Frontiers
|
Sep 19, 2025 |
|
Future Directions in FSGS Care
|
Sep 19, 2025 |
|
Integrating the Patient Voice in FSGS Management
|
Sep 19, 2025 |
|
Treatment Considerations for Pediatric Patients With FSGS
|
Sep 19, 2025 |
|
DEARA Versus SOC in FSGS Management: Clinical Trial Insights
|
Sep 19, 2025 |
|
Monitoring FSGS: Traditional and Novel Biomarkers
|
Sep 19, 2025 |
|
Emerging Therapies in Managing Adult and Pediatric Patients With FSGS: Latest Data
|
Sep 19, 2025 |
|
FSGS: Interpretation of Proteinuria Reduction Thresholds
|
Sep 19, 2025 |
|
Current FSGS Treatment Landscape: More Questions Than Answers
|
Sep 19, 2025 |
|
FSGS: When Solutions Fall Short
|
Sep 19, 2025 |
|
Real-World Evidence of Photobiomodulation Efficacy in Ocular Indications
|
Sep 16, 2025 |
|
Integration of Photobiomodulation Therapy into the Age-Related Macular Degeneration Treatment Landscape
|
Sep 16, 2025 |
|
Patient-Centered Care and Integration of Photobiomodulation Therapy into Clinical Practice
|
Sep 16, 2025 |
|
Best Practices for Optimized Photobiomodulation Treatment Effect: Candidate Selection
|
Sep 16, 2025 |
|
Sustaining Visual Benefits of Photobiomodulation in Dry Age-Related Macular Degeneration
|
Sep 16, 2025 |
|
Anatomical Outcomes from the LIGHTSITE III Trial
|
Sep 16, 2025 |
|
Clinical and Safety Outcomes from the LIGHTSITE III Trial
|
Sep 16, 2025 |
|
Photobiomodulation: A Non-Invasive Treatment for Ocular Disease and Trauma
|
Sep 16, 2025 |
|
Psoriasis and Obesity: Going Pound for Pound on Comprehensive, Patient-Centered Management
|
Sep 15, 2025 |
|
Collaborative Care for CRSwNP Expert and Patient Insights
|
Sep 12, 2025 |
|
Retina Case Review: Translating the Data Into Care
|
Sep 02, 2025 |
|
Insights and Updates: New Data on Next-Generation Retinal Treatments
|
Sep 02, 2025 |
|
Global Perspectives on Perioperative Immunotherapy in LA HNSCC
|
Aug 29, 2025 |
|
The Clinical Weight of TTR: What the Latest Data Reveal
|
Aug 28, 2025 |
|
Advances in the Treatment of Neuropsychiatric Symptoms of Alzheimer's Disease: Early Recognition, Diagnosis, and Innovative Emerging Therapies
|
Aug 28, 2025 |
|
Optimizing IgAN Care: Achieving Lower Proteinuria Targets with Combination Therapy
|
Aug 27, 2025 |
|
Multidisciplinary Collaboration Facilitates Multimodality Therapy
|
Aug 22, 2025 |
|
Managing Immune-Related Adverse Events in the Perioperative Setting
|
Aug 22, 2025 |
|
Applying Perioperative ICIs in Clinical Practice
|
Aug 22, 2025 |
|
Risk Stratification and Patient Selection for Perioperative ICIs
|
Aug 22, 2025 |
|
Emerging Evidence for Perioperative ICIs in Locally Advanced HNSCC
|
Aug 22, 2025 |
|
Rationale for Combining Radiation and Immunotherapy in Resectable Locally Advanced HNSCC
|
Aug 22, 2025 |
|
The Evolving Landscape of Resectable Locally Advanced HNSCC
|
Aug 22, 2025 |
|
Resectable Head & Neck Cancer: A Team-Based Approach to Perioperative Immunotherapy
|
Aug 22, 2025 |
|
Next-Generation Innovations: The Future of CELMoDs in Myeloma
|
Aug 21, 2025 |
|
Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
|
Aug 21, 2025 |
|
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
|
Aug 21, 2025 |
|
Real-World Ready: Practical Tips for Community Oncologists
|
Aug 21, 2025 |
|
Safety First: Navigating CELMoD-Associated Toxicities
|
Aug 21, 2025 |
|
Mastering the Sequence: CELMoDs Across Treatment Lines
|
Aug 21, 2025 |
|
Precision Targeting: Matching CELMoDs to the Right Patient With Myeloma
|
Aug 21, 2025 |
|
Data Dive: Clinical Evidence Behind CELMoDs
|
Aug 21, 2025 |
|
Molecular Magic: Decoding the Unique Mechanism of CELMoDs
|
Aug 21, 2025 |
|
Why CELMoDs Matter in Myeloma
|
Aug 21, 2025 |
|
Risk Reduction with GLP-1 RAs in Individuals with ASCVD and T2D: 2025 Update
|
Aug 21, 2025 |
|
Chairperson Perspective: Acromegaly Care: Individualized Diagnosis and Management Strategies
|
Aug 15, 2025 |
|
Continuity in Care: Strategies for Managing Growth Hormone Deficiency Through Life’s Stages
|
Aug 05, 2025 |
|
Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach
|
Aug 01, 2025 |
|
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
|
Jul 31, 2025 |
|
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
|
Jul 31, 2025 |
|
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
|
Jul 31, 2025 |
|
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
|
Jul 31, 2025 |
|
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
|
Jul 31, 2025 |
|
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
|
Jul 31, 2025 |
|
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
|
Jul 31, 2025 |
|
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
|
Jul 31, 2025 |
|
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
|
Jul 31, 2025 |
|
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
|
Jul 31, 2025 |
|
Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC
|
Jul 31, 2025 |
|
MET and Other Emerging Targets in Metastatic NSCLC
|
Jul 31, 2025 |
|
HER2-Driven Strategies in Metastatic NSCLC
|
Jul 31, 2025 |
|
Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC
|
Jul 31, 2025 |
|
Strategies in EGFR-mutated Unresectable Stage III NSCLC
|
Jul 31, 2025 |
|
The Current Therapeutic Landscape in Unresectable Stage III NSCLC
|
Jul 31, 2025 |
|
Applications of Emerging Data in Resectable NSCLC
|
Jul 31, 2025 |
|
Novel Therapies in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
|
Jul 31, 2025 |
|
Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)
|
Jul 31, 2025 |
|
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
|
Jul 30, 2025 |
|
ADCs Across the Spectrum of HER2 Expression in Metastatic Breast Cancer
|
Jul 29, 2025 |
|
Expert Recommendations and Key Takeaways
|
Jul 25, 2025 |
|
Ongoing Clinical Trials in AML With Menin Inhibitors
|
Jul 25, 2025 |
|
Emerging Directions in Menin-Directed AML Therapy
|
Jul 25, 2025 |
|
Applying Evidence to Clinical Practice
|
Jul 25, 2025 |
|
Managing Adverse Events Associated With Menin Inhibitors
|
Jul 25, 2025 |
|
Incorporating Guideline-Recommended Targeted Therapies Into R/R AML Management
|
Jul 25, 2025 |
|
Clinical Evidence on Monotherapy With Menin Inhibitors in R/R AML
|
Jul 25, 2025 |
|
Menin Inhibitors: Biologic and Clinical Rationale
|
Jul 25, 2025 |
|
Molecular Profiling as a Cornerstone of Precision AML Therapy
|
Jul 25, 2025 |
|
Stratifying Risk to Guide Therapy in R/R AML
|
Jul 25, 2025 |
|
Community Clinic: Translating Data Into Action ─ Practical Strategies for Optimizing First-Line RCC Management
|
Jul 25, 2025 |
|
Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
|
Jul 24, 2025 |
|
Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
|
Jul 24, 2025 |
|
Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
|
Jul 24, 2025 |
|
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
|
Jul 22, 2025 |
|
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
|
Jul 17, 2025 |
|
How Do Patient Experiences and PAH Perspectives Vary Across Regions and Cultures Worldwide?
|
Jul 15, 2025 |
|
PROMs: Role in Clinical Research and Contributions to PAH Patient Perspectives
|
Jul 15, 2025 |
|
PROMs in Clinical Practice: Impacting Treatment Decisions
|
Jul 15, 2025 |
|
What Challenges and Triumphs Do Patients Face While Living With PAH?
|
Jul 15, 2025 |
|
A Comparison of PROMs and How to Use Them in Clinical Practice for PAH
|
Jul 15, 2025 |
|
Patient-Reported Outcome Measures (PROMs): Valuable Insights Into the Lived Experience of PAH
|
Jul 15, 2025 |
|
Integrating Palliative Care in Pulmonary Hypertension
|
Jul 15, 2025 |
|
Aligning PAH Treatment Plans With Key Care Goals and Your Patients’ Priorities
|
Jul 15, 2025 |
|
Managing Travel With PAH: Logistics, Medications, Oxygen, and Emergency Preparedness
|
Jul 15, 2025 |
|
The Latest Patient-Centered Recommendations From the 7th World Symposium on PH
|
Jul 15, 2025 |
|
Chairperson’s Perspective: Precision in Practice: Advancing EGFR-Altered Metastatic NSCLC Through Guideline-Concordant, Case-Based Learning
|
Jul 14, 2025 |
|
Treatment of a Broader Population of Patients With DMD
|
Jul 14, 2025 |
|
Optimizing VNS Parameters: Keys to Therapeutic Success
|
Jul 09, 2025 |
|
QoL Matters: Brain Stem Stimulation in Patients With Unipolar Depression
|
Jul 09, 2025 |
|
VNS: Beyond Seizure Control
|
Jul 09, 2025 |
|
Epilepsy: Beyond Seizure Impact
|
Jul 09, 2025 |
|
Differentiating Neuromodulation Therapies: VNS, DBS, ECT, TMS
|
Jul 09, 2025 |
|
Stemming the Tide on MASLD/MASH: It Starts on the Frontlines in Endocrinology and Primary Care Clinics
|
Jul 08, 2025 |
|
PH Management in Unique Patients and Conditions
|
Jul 03, 2025 |
|
New and Emerging PAH Therapies and Approaches: A Mixture of Hope and Complexity
|
Jul 03, 2025 |
|
Pulmonary Hypertension: Getting the Right Diagnosis and Knowing When to Refer
|
Jul 03, 2025 |
|
Enhancing Diagnosis, Treatment, and Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Novel Oral Therapeutics
|
Apr 25, 2025 |
|
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
|
Mar 31, 2025 |
|
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
|
Mar 31, 2025 |
|
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
|
Mar 31, 2025 |
|
From Guidelines to Practice: First-Line Treatment Choices in mCRC
|
Mar 31, 2025 |
|
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
|
Mar 31, 2025 |
|
Key Patient Counseling Issues Surrounding FNAIT and Its Risk in Subsequent Pregnancies
|
Jan 31, 2025 |
|
Nipocalimab: An FcRn Inhibitor and Its Role in Treating HDFN
|
Jan 31, 2025 |
|
Neonatal FcRn Inhibition: A New Pathway for Addressing the Alloimmune Disorders of Pregnancy
|
Jan 31, 2025 |
|
Screening for FNAIT: Anticipating HPA-1a Incompatibility
|
Jan 31, 2025 |
|
Managing the “Next Pregnancy” in Patients With an FNAIT-Affected First Child
|
Jan 31, 2025 |
|
Current Management Strategies for FNAIT
|
Jan 31, 2025 |
|
Current Diagnostic Signs, Symptoms, and Lab Tests for FNAIT
|
Jan 31, 2025 |
|
Classification/Suspecting a Diagnosis of FNAIT/NAIT
|
Jan 31, 2025 |
|
Fetal/Neonatal Alloimmune Thrombocytopenia (FNAIT): The Platelet Equivalent of Rh Disease
|
Jan 31, 2025 |
|
The Alloimmune Disorders of Pregnancy
|
Jan 31, 2025 |
|
Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL
|
Jan 14, 2025 |
|
Can We Talk? Optimizing Patient Buy-In to the Management of Endometriosis
|
Aug 09, 2024 |
|
Pre- and Postoperative Use of GnRH Antagonists
|
Aug 09, 2024 |
|
The Integral Role of GnRH Antagonists in the Management of Endometriosis
|
Aug 09, 2024 |
|
Changing the Paradigm in the Management of Endometriosis: Moving Away From “Surgery First” to “Pharmacologic Therapy First”
|
Aug 09, 2024 |
|
Capturing the Impact of Endometriosis on Health-Related QoL: The Role of Patient Questionnaires
|
Aug 09, 2024 |
|
Early Diagnosis: Its Pivotal Role in Optimizing Outcomes in Patients With Endometriosis – Psychosocial and Physical Consequences
|
Aug 09, 2024 |
|
Improving Outcomes and Addressing Racial Disparities in Patients With HR+/HER2- Early Breast Cancer: A Case-Based Learning Lab
|
Apr 30, 2024 |
|
Expert Answers to Common Questions on Response Matters: Transforming the Standard of Care in CML by Mastering Response-Guided Treatment
|
Feb 13, 2024 |
|
Chairperson’s Perspective: CDK 4/6 Inhibitors: Practice-Changing Implications of Targeted Therapies in HR+/HER2- Breast Cancer
|
Dec 31, 2023 |
|
Should We Look for Gout in the Cardiology Clinic?
|
Oct 24, 2023 |
|
What Are the Emerging Therapies for Managing Gout?
|
Oct 24, 2023 |
|
What’s New About Gout? Rheumatology Perspective
|
Oct 24, 2023 |
|
What’s New About Gout? Nephrology Perspective
|
Oct 24, 2023 |
|
Can You Manage Patients With Uncontrolled Gout More Effectively?
|
Oct 24, 2023 |
|
Treat or Refer: Who Is Responsible for Managing Gout?
|
Oct 24, 2023 |
|
Center of the Target: Which Patients Are Most Likely to Develop Gout?
|
Oct 24, 2023 |
|
Is Managing Gout in the Nephrology Clinic a Challenge?
|
Oct 24, 2023 |
|
Is Gout Hiding in the Nephrology Clinic?
|
Oct 24, 2023 |
|
Gout Beyond the Joints: What’s the Hidden Danger?
|
Oct 24, 2023 |
|
Expert Answers to Common Questions About MET Exon 14–Skipping Mutations in NSCLC
|
Dec 28, 2022 |
|
Improved Outcomes in mCRPC with PSMA-Directed Diagnostics and Therapies
|
Aug 31, 2022 |
|
Evolving Perspectives in PIK3CA-related Overgrowth Spectrum Diagnosis & Treatment
|
Aug 26, 2022 |
|
Optimizing the Care and Quality of Life for Patients with ADPKD – Part 4: Emerging Therapies
|
Aug 31, 2021 |
|
A Novel Therapeutic Approach in Myeloid Malignancies: Targeting the Neddylation Pathway
|
Aug 31, 2021 |
|
Optimizing the Care and Quality of Life for Patients with ADPKD – Part 3: Management
|
Aug 16, 2021 |
|
Optimizing the Care and Quality of Life for Patients with ADPKD – Part 2: Progression and Prognostication
|
Aug 05, 2021 |
|
Optimizing the Care and Quality of Life for Patients with ADPKD – Part 1: Detection and Diagnosis
|
Aug 04, 2021 |
|
The Clinical Significance of Imaging in the Management of ADPKD
|
Jun 28, 2021 |
|
Expert Answers to Common Questions for the Management of Hemophilia A
|
Jul 11, 2019 |